{
  "label": "q_cs03_q12_severity",
  "artifact_type": "question",
  "artifact_id": "sha256:46d266c2dcc577dd1f0da6ef3bc2d8ebc256bea357a73e2edd69a61139e05e70",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:bd89cf127fe8ce28af2609c702fd06647b82347034cf0bfb835b2f19a4d19bd1",
    "sha256:526bf0877b15ba594954d8544c6493f2535bc8acb2239824a0eeeb941d801b2d"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:44.859923",
  "content": "{\n  \"question_id\": \"cs03_q12_severity\",\n  \"scope_id\": \"clinical_signal_03\",\n  \"checkpoint_after\": 20,\n  \"question_type\": \"severity_assessment\",\n  \"prompt\": \"How would you assess the severity of the hepatic signal and the urgency of protocol intervention?\",\n  \"ground_truth\": {\n    \"canonical_answer\": \"High severity. Two subjects have met Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN), which is a recognized indicator of potential drug-induced liver injury. The signal is escalating and protocol amendment is urgent to prevent further SAEs.\",\n    \"required_evidence_refs\": [\n      \"clinical_signal_03_ep_017\",\n      \"clinical_signal_03_ep_019\"\n    ],\n    \"key_facts\": [\n      \"ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases\",\n      \"the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity\",\n      \"the adverse signal is hepatic (ALT/AST elevation), not renal \\u2014 kidney function markers remain stable while liver enzymes diverge\",\n      \"the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns\",\n      \"musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver\",\n      \"multi-site signal distribution rules out site-specific confounders as causal explanation\",\n      \"Site 07 lab equipment issue is not the cause of ALT elevations\",\n      \"ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event\"\n    ]\n  }\n}",
  "metadata": {
    "question_id": "cs03_q12_severity",
    "question_type": "severity_assessment",
    "checkpoint_after": 20,
    "scope_id": "clinical_signal_03",
    "layer_name": "questions",
    "layer_level": 3,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "9c7407eca42fe01179a0c1b0be7fb128c3de17fce756665e7fb962a0d274072f",
      "components": {
        "transform": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
        "inputs": "c8306a32ee5871fb"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
      "components": {
        "transform_id": "3176c030aaa3a69e",
        "source": "929fe273ac2dab06",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}